How Bris­tol My­er­s' buy­out of­fer for Mi­rati dwin­dled by bil­lions of dol­lars

Af­ter years of be­ing a ru­mored biotech buy­out tar­get, Mi­rati was ul­ti­mate­ly ac­quired by Bris­tol My­ers Squibb ear­li­er this month for $4.8 bil­lion. But the phar­ma buy­er once of­fered more than dou­ble that price, a se­cu­ri­ties fil­ing re­veals.

Through the Oct. 8 deal, Bris­tol My­ers is en­ter­ing a ri­val­ry with Am­gen in tar­get­ing KRAS, the can­cer-dri­ving mu­ta­tion once deemed un­drug­gable. The SEC fil­ing, which de­tails the ne­go­ti­a­tions lead­ing up to the deal, il­lus­trates how the $58 a share that Bris­tol My­ers agreed to pay for Mi­rati was cut down as the hope and hype around KRAS dwin­dled over the years’ worth of in­ter­est in the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER